中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 10
Oct.  2013
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2013  >  29(10): 793-796

Clinical application of perfusion- weighted MRI in liver diseases

DOI: 10.3969/j.issn.1001-5256.2013.10.018

  • Department of Radiology, Shanghai Fifth People's Hospital Affiliated to Fudan University

  • Received Date: 2013-02-25
  • Published Date: 2013-10-20
    Abstract
  • Conventional magnetic resonance imaging ( MRI) can provide the characteristics of abdominal solid tumors such as sizes and shapes, while perfusion- weighted imaging can provide additional information on the blood supply, vascular distribution, and vascular permeability of tumors. These information is useful for diagnosis and differential diagnosis, tumor staging, and evaluation of treatment outcome.The procedures and common metrics of perfusion- weighted MRI are reviewed, and its applications in liver fibrosis staging, differential diagnosis of liver tumors, detection of occult or small liver metastases, and evaluation of non- surgical treatment outcome of liver cancer or metastasis are presented. It is suggested that greater effort is needed to promote the clinical use of MRI, as it causes no radiation damage, despite the fact that the use of MRI is subject to patient conditions.

     

    • FullText(HTML)
    • References(30)
  • [1]JIA WX, CHEN M.Application of function magnetic resonance imaging[M].Peking:People's Military Medical Press, 2012:98-100. (in Chinese) 贾文霄, 陈敏.磁共振功能成像临床应用[M].北京:人民军医出版社, 2012:98-100.
    [2]JIN N, DENG J, CHADASHVILI T, et al.Carbogen gas-challenge BOLD MR imaging in a rat model of diethylnitrosamine-induced liver fibrosis[J].Radiology, 2010, 254 (1) :129-137.
    [3]LIN GW, ZHOU CW.The advancement of functional magnetic resonance imaging in tumor diagnosis and appreciation of curative effects of liver disease[J].Oncol Progr, 2007, 5 (5) :442-448. (in Chinese) 林光武, 周纯武.磁共振功能成像在肝脏疾病的诊断及疗效评价方面的应用进展[J].癌症进展, 2007, 5 (5) :442-448.
    [4]KIM AY, KIM YK, LEE MW, et al.Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis[J].Acta Radiol, 2012, 53 (8) :830-838.
    [5]KOJIRO M, WANLESS IR, ALVES V, et al.Pathologic diagnosis of early hepatocellular carcinoma:a report of the international consensus group for hepatocellular neoplasia[J].Hepatology, 2009, 49 (2) :658-664.
    [6]TAJIMA T, HONDA H, TAGUCHI K, et al.Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules:CT angiography and pathologic correlation[J].AJR Am J Roentqenol, 2002, 178 (4) :885-897.
    [7]PARENTE DB, PEREZ RM, EIRAS-ARAUJO A, et al.MR imaging of hypervascular lesions in the cirrhotic liver:a diagnostic dilemma[J].Radiographics, 2012, 32 (3) :767-787.
    [8]MATSUI O, KOBAYASHI S, SANADA J, et al.Hepatocelluar nodules in liver cirrhosis:hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis[J].Abdom Imaging, 2011, 36 (3) :264-272.
    [9]GUAN S, ZHAO WD, ZHOU KR, et al.Assessment of hemodynamics in precancerous lesion of hepatocellular carcinoma:Evaluation with MR perfusion[J].World J Gastroenterol, 2007, 13 (8) :1182-1186.
    [10]RHEE H, KIM MJ, PARK YN, et al.Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria[J].J Magn Reson Imaging, 2012, 35 (2) :393-398.
    [11]XU H, XIE JX, LI X, et al.Perfusion-weighted MRI in evaluating the intranodular hemodynamic characteristics of dysplastic nodules and hepatocellular carcinomas in an experimental rat model[J].J Magn Reson Imaging, 2008, 27 (1) :102-109.
    [12]REN S, YE ZX, ZHU LM.Pathological and imaging features of multistep process of cirrhosis nodules[J].J Clin Hepatol, 2011, 27 (4) :425-428. (in Chinese) 任崧, 叶兆祥, 朱理珉.肝硬化结节多步癌变的病理及影像学表现[J].临床肝胆病杂志, 2011, 27 (4) :425-428.
    [13]KUDO M.Diagnostic imaging of hepatocellular carcinoma:recent progress[J].Oncology, 2011, 81 (Suppl 1) :73-85.
    [14]TSUSHIMA Y, BLOMLEY M, YOKOYAMA H, et al.Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver?[J].Dig Dis Sci, 2001, 46 (10) :2113-2119.
    [15]LI ZG, HUANG JX, LI SZ, et al.Blood supply of liver metastasis[J].J Peking Univ:Health Sci, 2008, 40 (2) :146-150. (in Chinese) 李智岗, 黄景香, 李顺宗, 等.肝转移瘤的血供[J].北京大学学报:医学版, 2008, 40 (2) :146-150.
    [16]DEZSO K, BUGYIK E, PAPP V, et al.Development of arterial blood supply in experimental liver metastases[J].Am J Pathol, 2009, 175 (2) :835-843.
    [17]FIORENTINI G, ALIBERTI C, TILLI M, et al.Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer:final results of a phase III study[J].Anticancer Res, 2012, 32 (4) :1387-1395.
    [18]KIM T, HORI M, ONISHI H.Liver masses with central or eccentric scar[J].Semin Ultrasound CT MR, 2009, 30 (5) :418-425.
    [19]DONATI F, BORASCHI P, GIGONI R, et al.Focal nodular hyperplasia of the liver:diffusion and perfusion MRI characteristics[J].Magn Reson Imaging, 2013, 31 (1) :10-16.
    [20]LEPORQ B, DUMORTIER J, PILLEUL F, et al.3D-liver perfusion MRI with the MS-325 blood pool agent:a noninvasive protocol to asses liver fibrosis[J].J Magn Reson Imaging, 2012, 35 (6) :1380-1387.
    [21]KIM BH, LEE JM, LEE YJ, et al.MR elastography for noninvasive assessment of hepatic fibrosis:experience from a tertiary center in Asia[J].J Magn Reson Imaging, 2011, 34 (5) :1110-1116.
    [22]ZENG Y, ZHAO JN, WU W, et al.Establishment of liver fibrosis in rabbit model and quantitative study on hepatic perfusion with dynamic whole-liver 3D MR imaging[J].Chin J Hepatol, 2009, 17 (5) :350-353. (in Chinese) 曾燕, 赵建农, 吴伟, 等.家兔肝纤维化模型的建立及三维全肝动态磁共振灌注成像对纤维化分期的量化价值[J].中华肝脏病杂志, 2009, 17 (5) :350-353.
    [23]HAGIWARA M, RUSINEK H, LEE VS, et al.Advanced liver fibrosis:diagnosis with 3D whole-liver perfusion MR imaging-Initial experience[J].Radiology, 2008, 246 (3) :926-934.
    [24]THNG CH, KOH TS, COLLINS DJ, et al.Perfusion magnetic resonance imaging of the liver[J].World J Gastroenterol, 2010, 16 (13) :1598-1609.
    [25]HIRASHIMA Y, YAMADA Y, TATEISHI U, et al.Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis[J].Int J Cancer, 2012, 130 (10) :2359-2365.
    [26]CAO Y, WANG HS, JOHNSON TD, et al.Prediction of liver function by using magnetic resonance-based portal venous perfusion imaging[J].Int J Radiat Oncol, 2013, 85 (1) :258-263.
    [27]MIYAZAKI K, ORTON MR, DAVIDSON RL, et al.Neuroendocrine tumor liver metastases:use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response[J].Radiology, 2012, 263 (1) :139-148.
    [28]LARSON AC, WANG D, ATASSI B, et al.Transcatheter intraarterial perfusion:MR monitoring of chemoembolization for hepatocellular carcinoma-feasibility of initial clinical translation[J].Radiology, 2008, 246 (3) :964-971.
    [29]CHEN Z, GUO Y, ZHENG XL, et al.Value of MR perfusion imaging after intervention treatment of hepatic cancer[J].ChineseGerman J Clin Oncol, 2009, 8 (1) :33-36.
    [30]ZENG MS.The emphasizing MRI technology on application of liver-the clinical diagnostic value and advance of small hepatocellular carcinoma[J].Chin Comput Med Imag, 2011, 17 (5) :385-389. (in Chinese) 曾蒙苏.重视肝脏MRI技术应用——小肝癌临床诊断价值和进展[J].中国医学计算机成像杂志, 2011, 17 (5) :385-389.
    • Relative Articles

  • Relative Articles

    [1]Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
    [2]Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
    [3]Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
    [4]Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
    [5]Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
    [6]Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
    [7]Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
    [8]Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
    [9]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [10]Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
    [11]Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
    [12]Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
    [13]Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng.

    Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
    [14]Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
    [19]Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(11)

    1. 肖春桃，李贤秋，甘佩灵，潘潇，周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
    2. 王彤，牛焕章，杜廷伟，魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
    3. 姜炅，袁佳，史海涛，戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
    4. 李英，高磊，胡扬喜，胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
    5. 吕靖，董思思，顾宏图，赵长青，刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
    6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
    7. 牟思玉，杨哲，吴力群，邱轩，郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
    8. 张津瑜，陈文显，沈华，王雁，张国雷，慎华平，吴万波，魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
    9. 邢文立，李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
    10. 李志州，向俊峰，周威，唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
    11. 王士浩，张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

    Other cited types(12)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.1 %FULLTEXT: 15.1 %META: 80.5 %META: 80.5 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.7 %其他: 4.7 %其他: 0.6 %其他: 0.6 %Bengaluru: 0.2 %Bengaluru: 0.2 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %Japan: 0.1 %Japan: 0.1 %Kennedy Town: 0.2 %Kennedy Town: 0.2 %North Point: 0.2 %North Point: 0.2 %Seattle: 0.1 %Seattle: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.4 %[]: 0.4 %上海: 9.5 %上海: 9.5 %东莞: 0.6 %东莞: 0.6 %中卫: 0.1 %中卫: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.1 %佳木斯: 0.1 %北京: 9.3 %北京: 9.3 %南京: 0.6 %南京: 0.6 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.1 %台州: 0.1 %合肥: 0.3 %合肥: 0.3 %周口: 0.1 %周口: 0.1 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.1 %唐山: 0.1 %喀什: 0.2 %喀什: 0.2 %圣地亚哥: 0.1 %圣地亚哥: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %常德: 0.1 %常德: 0.1 %广州: 1.0 %广州: 1.0 %张家口: 1.4 %张家口: 1.4 %成都: 0.2 %成都: 0.2 %扬州: 0.3 %扬州: 0.3 %无锡: 0.2 %无锡: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.5 %杭州: 0.5 %柳州: 0.1 %柳州: 0.1 %武汉: 0.3 %武汉: 0.3 %水牛城: 0.1 %水牛城: 0.1 %永州: 0.2 %永州: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沈阳市和平区: 0.1 %沈阳市和平区: 0.1 %泰安: 0.2 %泰安: 0.2 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.6 %济南: 0.6 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.5 %深圳: 0.5 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %百色: 0.2 %百色: 0.2 %眉山: 0.1 %眉山: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %秦皇岛: 0.2 %秦皇岛: 0.2 %米兰: 0.1 %米兰: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城市东昌府区: 0.1 %聊城市东昌府区: 0.1 %芒廷维尤: 38.2 %芒廷维尤: 38.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.6 %莫斯科: 0.6 %莱芜: 0.1 %莱芜: 0.1 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.1 %萍乡: 0.1 %葵涌: 0.1 %葵涌: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.2 %西宁: 14.2 %西安: 2.2 %西安: 2.2 %西安市新城区: 0.1 %西安市新城区: 0.1 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %郑州: 0.2 %郑州: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 0.6 %长春: 0.6 %长沙: 2.2 %长沙: 2.2 %长治: 0.1 %长治: 0.1 %雅安: 1.0 %雅安: 1.0 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruChinaIndiaJapanKennedy TownNorth PointSeattleUnited States[]上海东莞中卫佛山佳木斯北京南京南宁南阳印度泰米尔纳德厦门台北台州合肥周口哈尔滨唐山喀什圣地亚哥大连天津常德广州张家口成都扬州无锡晋城杭州柳州武汉水牛城永州沈阳沈阳市和平区泰安泰州洛阳济南海得拉巴深圳渭南湘潭漯河百色眉山石嘴山石家庄秦皇岛米兰美国伊利诺斯芝加哥聊城市东昌府区芒廷维尤芝加哥苏州莫斯科莱芜菏泽萍乡葵涌衢州西宁西安西安市新城区许昌诺沃克贵阳赤峰运城郑州重庆长春长沙长治雅安青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2993) PDF downloads(608) Cited by(23)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[103]TodayPV[185]Online[46]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return